Immunotherapy-based first-line treatment of intermediate- and poor-risk advanced renal cell carcinoma: number needed to treat and cost of preventing an event from the perspective of the Brazilian private healthcare system.

Autor:	Casagrande Drozda Oliveira, Ana Paula, Finardi Roubik, Camila, T. D. Dyer, Matthew, Del Grossi Neusquen, Lucienne Pereira, Zago Marcolino, Miriam Allein, Antonini Ribeiro, Rodrigo, May, Jessica R.
Předmět:	RENAL cell carcinoma MEDICAL care costs COMMERCIAL products COST effectiveness MEDICAL care PROGRESSION-free survival
Zdroj:	JBES: Brazilian Journal of Health Economics / Jornal Brasileiro de Economia da Saúde; Dec2021, Vol. 13 Issue 3, p258-267, 10p
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu